Oxybutynin Chloride
Brand name: Oxybutynin Chloride Er
Rank #242 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$53.4M
Total Cost
1,872,901
Total Claims
$53.4M
Total Cost
62,249
Prescribers
$29
Cost per Claim
278,509
Beneficiaries
3,476,553
30-Day Fills
$858
Avg Cost/Provider
30
Avg Claims/Provider
Share of Medicare Part D Spending
0.02%
of total Medicare Part D spending
$53.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $53.4M total
Top Prescribers of Oxybutynin Chloride
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Steven Jensen | Urology | Saginaw, MI | 1,450 | $87K |
| 2 | Igor Ryndin | Urology | Brooklyn, NY | 1,510 | $69K |
| 3 | Felix Davelman | Urology | Middletown, NY | 941 | $36K |
| 4 | Stephanie Kracker | Physician Assistant | Marysville, OH | 812 | $36K |
| 5 | Leonard Renfer | Urology | Salinas, CA | 544 | $33K |
| 6 | Jorge Pando | Obstetrics & Gynecology | Miami Lakes, FL | 1,799 | $31K |
| 7 | Sun Kim | Urology | San Bernardino, CA | 618 | $26K |
| 8 | Robert Humble | Urology | Monroe, LA | 1,023 | $25K |
| 9 | Norman Colon-Casasnovas | Urology | Dorado, PR | 1,084 | $23K |
| 10 | Joseph Mouchizadeh | Urology | Ronceverte, WV | 594 | $23K |
| 11 | Christopher Vallorosi | Urology | Dover, DE | 482 | $23K |
| 12 | Nancy Wilcox | Nurse Practitioner | Rochester, NY | 671 | $22K |
| 13 | Joshua Spendlove | Urology | Kennewick, WA | 630 | $22K |
| 14 | Michael Ahearn | Hospitalist | Kewanee, IL | 464 | $22K |
| 15 | Melissa Reigle | Urology | Willoughby, OH | 528 | $21K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 239 | Amifampridine Phosphate (Firdapse) | $54.4M | 1,203 |
| 240 | Dapaglifloz Propaned/Metformin (Xigduo Xr) | $54.4M | 58,629 |
| 241 | Buspirone Hcl (Buspirone Hcl) | $53.7M | 2,868,147 |
| 242 | Oxybutynin Chloride (Oxybutynin Chloride Er) | $53.4M | 1,872,901 |
| 243 | Raltegravir Potassium (Isentress) | $53.0M | 25,491 |
| 244 | Belumosudil Mesylate (Rezurock) | $52.3M | 2,280 |
| 245 | Pegloticase (Krystexxa) | $52.2M | 1,134 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology